Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Jazz Pharmaceuticals (JAZZ)

Jazz Pharmaceuticals expects to meet its 2025 total revenue guidance range

Positive Impact 3 of 5 guidance Written later

Jazz Pharmaceuticals said in a January 12, 2026 filing that it expects to meet its previously announced total revenue guidance range for the year ended December 31, 2025. The company will present the update at the J.P. Morgan Healthcare Conference on January 13, 2026, and says the 2025 results have not been finalized and actual results may differ.

Key points

  • Expects to meet the 2025 total revenue guidance range provided on November 5, 2025
  • Presentation slides show Xywav and Epidiolex each with $1B+ in 2025 sales, and Modeyso with nearly $50 million in 2025 revenue
  • Figures are unaudited; the company states 2025 financial results have not been finalized and actual results may differ
  • Update to be presented January 13, 2026 at the J.P. Morgan Healthcare Conference in San Francisco

The filing

CompanyJazz Pharmaceuticals (JAZZ)
Form8-K, current report
Filed with the SECJan 12, 2026, 9:01 AM ET
Accession number0001193125-26-009899

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:11 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 12, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.